




Ask The Doctor

Study Participants Help Find New Treatments

by *Timothy L. Vollmer, M.D.*

(NAPSA)—A new clinical trial called Bravo could offer an option to thousands of Americans living with multiple sclerosis (MS).

According to the National Multiple Sclerosis Society, approximately 400,000 Americans have MS, with 200 people being diagnosed every week.



Dr. Timothy L. Vollmer

The most common form of MS is the relapsing-remitting form, or RRMS, which affects nearly 85 percent of people with MS. People with RRMS experience unpredictable attacks,

known as relapses, followed by periods of relative quiet with no new signs of disease activity, which can last months or even years.

Fighting RRMS

There is currently no cure for MS, and while available treatments may slow the disease, they require injections or infusions, and may cause adverse reactions or discomfort.

In order to find new ways to treat the condition, physicians and patients are collaborating on a global study called Bravo, which is exploring the effectiveness, safety and tolerability of laquinimod, a once-daily, oral investigational drug for RRMS. Study participants are hopeful that



A new clinical trial may provide people with a common form of multiple sclerosis with an investigational oral treatment option.

research has the ability to lead to improved therapies that are convenient, efficacious and safe.

Who Can Participate

People with a confirmed diagnosis of RRMS can participate in the study if they are between 18 and 55 years old and have had at least one relapse in the last 12 months or two in the last 24 months. Visit www.TevaClinicalTrials.com or www.ClinicalTrials.gov, or call 1-800-840-5601 for more information.

Why Get Involved?

While there is no guarantee that a participant's RRMS symptoms will subside, he or she may be helping future patients with the disease.

• *Dr. Vollmer is director of North American Research Committee On Multiple Sclerosis (NARCOMS).*



Note to Editors: Bravo is a pivotal Phase III study sponsored by Teva Pharmaceutical Industries Ltd.